<DOC>
	<DOCNO>NCT01517529</DOCNO>
	<brief_summary>The major goal project identify role immune response emergence protease inhibitor mutant therapy .</brief_summary>
	<brief_title>Evaluating Role Immune Responses Emergence Protease Inhibitor Mutations</brief_title>
	<detailed_description>Objective 1 : Evaluate role immune response determine emergence HCV NS3 resistance mutation protease inhibitor therapy Hypothesis 1 ( HT 1 ) : Low HLA binding peptide contain protease inhibitor resistance mutation associate emergence protease inhibitor mutant therapy failure treatment . Hypothesis 2 ( HT 2 ) : A hole T cell repertoire may allow emergence protease inhibitor mutant protease inhibitor therapy lead loss immune responses mutant failure treatment .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>All chronically HCVinfected patient fail pegIFN RBV therapy eligible combine treatment PI therapy enrol . Briefly , include : 1 . Male female 2 . Age 18 65 3 . Chronic HCV infection evidence liver biopsy persistent HCV viremia &gt; 6 month 4 . Treatment experience classified nonresponder relapser prior interferonbased therapy . Exclusion criterion : 1 . Treatment na√Øve chronically HCVinfected patient . 2 . Patients history inflammatory bowel disease ( IBD ) suspect IBD , autoimmune disease , include rheumatoid arthritis , patient systemic immunomodulators . 3 . Pregnancy 4 . HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>